Who are Ropinirole XL (formerly CR)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Olanzapine-Fluoxetine Combination, Fluoxetine+Olanzapine, Quetiapine 600mg, olanzapine + fluoxetine, Escitalopram+Aripiprazole, Quetiapine Fumarate Sustained Release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropinirole-xl-formerly-cr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ropinirole XL (formerly CR) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropinirole XL (formerly CR) (Ropinirole XL (formerly CR)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dopamine agonist. Area: Neurology.

phase 3 dopamine agonist D2 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Ropinirole XL (formerly CR) (Ropinirole XL (formerly CR)) — GlaxoSmithKline. Ropinirole XL is a dopamine agonist that works by stimulating dopamine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ropinirole XL (formerly CR) TARGET	Ropinirole XL (formerly CR)	GlaxoSmithKline	phase 3	dopamine agonist	D2 receptor
Olanzapine-Fluoxetine Combination	Olanzapine-Fluoxetine Combination	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + SSRI combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Fluoxetine+Olanzapine	Fluoxetine+Olanzapine	University Health Network, Toronto	marketed	SSRI + atypical antipsychotic combination	Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine 600mg	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
olanzapine + fluoxetine	olanzapine + fluoxetine	University of Florida	marketed	Atypical antipsychotic + SSRI combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Escitalopram+Aripiprazole	Escitalopram+Aripiprazole	Ministry of Health & Welfare, Korea	marketed	SSRI + atypical antipsychotic combination	Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT1A receptor
Quetiapine Fumarate Sustained Release	Quetiapine Fumarate Sustained Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (dopamine agonist class)

GlaxoSmithKline · 3 drugs in this class
Gary Archer Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ropinirole XL (formerly CR) — Competitive Intelligence Brief. https://druglandscape.com/ci/ropinirole-xl-formerly-cr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab